Tumor News and Research

RSS

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

26 Jul 2024

Experimental cancer drug could make thinking easier for individuals with Rett syndrome

An experimental cancer drug could make thinking easier for individuals with Rett syndrome, a rare disorder linked to autism, according to new research from the University of California San Diego -; a discovery that could lead to therapies for patients with other neurological conditions.

25 Jul 2024

Fecal microbiota transplants can boost the effectiveness of immunotherapy in gastrointestinal cancers

Findings from a small, proof-of-concept clinical trial have suggested that fecal microbiota transplants (FMTs) can boost the effectiveness of immunotherapy in a range of gastrointestinal cancers.

25 Jul 2024

FAU researcher wins $701,000 grant to revolutionize cancer treatment

While chemotherapy has advanced in personalization, personalized radiation therapy for cancer remains underdeveloped.

25 Jul 2024

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

25 Jul 2024

CHEST releases new clinical guideline for managing central airway obstruction

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on central airway obstruction (CAO).

24 Jul 2024

AI model enhances DCIS diagnosis using tissue image analysis

Ductal carcinoma in situ (DCIS) is a type of preinvasive tumor that sometimes progresses to a highly deadly form of breast cancer. It accounts for about 25 percent of all breast cancer diagnoses.

24 Jul 2024

Proteomic signatures enhance risk prediction for both common and rare diseases

Researchers have developed sparse prediction models combining plasma proteins and clinical data to predict the 10-year risk of 218 diseases. The study, involving over 41,000 participants, highlights the enhanced predictive power of proteomic signatures.

24 Jul 2024

Associations between gut microbes and Alzheimer’s disease

Researchers reviewed existing data on the role of the gut microbiome in Alzheimer’s disease (AD) pathogenesis.

24 Jul 2024

Oral-gut axis: How mouth bacteria impact your overall health

A recent review in Nature Reviews Microbiology highlights how oral and gut microbiomes interact, impacting overall human health. Oral microorganisms can enter the gut, contributing to dysbiosis and various diseases, necessitating further research on these complex interactions.

24 Jul 2024

Exploring non-coding RNAs as regulators of notch signaling in breast cancer

Breast cancer (BC) remains one of the most challenging cancers to treat, primarily due to its heterogeneity and propensity for metastasis.

23 Jul 2024

Unraveling the role of TAL1 and miR-146b-5p in T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that arises from the malignant transformation of T-cell progenitors.

23 Jul 2024

New strategy for mRNA nanocarriers using triphenyl phosphonium

Among the vastly different ways of tackling a disease, controlling the genetic expression of cells is undoubtedly one of the most powerful. Over the past few decades, scientists have come up with dozens of innovative strategies that involve using messenger RNA (mRNA) to 'force' cells to build specific proteins. These mRNA-based therapies have recently gained prominence as vaccines against infectious diseases like COVID-19. Additionally, they hold significant potential for treating cancer and genetic disorders.

23 Jul 2024

Challenges and opportunities in rare tumor research

Ning Li et al., at Chinese Academy of Medical Sciences and Peking Union Medical College, China, provides a comprehensive review on the challenges and opportunities in the field of rare tumor research and management.

22 Jul 2024

DDX41: A unique player in myeloid leukemogenesis

A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, "DDX41 and its unique contribution to myeloid leukemogenesis."

19 Jul 2024

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center.

19 Jul 2024

Research may pave the way for systemic targeted therapy for patients with pseudomyxoma peritonei

Published in Clinical Cancer Research, results of a preclinical study led by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Stem Cells and Cancer Group, headed by Héctor G. Palmer, pave the way for systemic targeted therapy in patients with pseudomyxoma peritonei, a rare form of cancer with very few therapeutic options available.

19 Jul 2024

Physical modulation of the tumor microenvironment to enhance cancer therapy

Announcing a new article publication for BIO Integration journal. The tumor microenvironment (TME) has a crucial role in tumor development, metastasis, and recurrence.

19 Jul 2024

Deciphering the role of RET in cancer and breakthroughs in targeted treatments

Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) receptor tyrosine kinase in cancer development and the advancements in RET-targeted cancer therapies.

19 Jul 2024

FDA approval of lifileucel: A milestone in tumor-infiltrating lymphocyte therapy for advanced melanoma

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy.

18 Jul 2024